DF Deutsche Forfait AG Reports Another Successful Year and Expands into Blood Plasma Market

Financial Highlights and Annual Report

DF Deutsche Forfait AG, a German company specializing in export finance services, has concluded another successful financial year, as detailed in their recently published Annual Report for 2024. The report, released on April 30, 2025, highlights the company’s continued growth and dynamic performance in the financial services sector. DF Deutsche Forfait AG, listed on the Frankfurt Stock Exchange, has maintained a strong market presence with a market capitalization of 18,070,000 EUR and a price-to-earnings ratio of 15.69. The company’s close price on April 28, 2025, was 1.48 EUR, reflecting a stable performance within the 52-week range of 1.33 to 1.76 EUR.

Preliminary Financial Announcements

In anticipation of the detailed financial reports, DF Deutsche Forfait AG issued a preliminary announcement on April 29, 2025, in compliance with Articles 114, 115, and 117 of the German Securities Act (WpHG). This announcement, disseminated through EQS News, underscores the company’s commitment to transparency and regulatory compliance. The preliminary financial statements are expected to provide further insights into the company’s financial health and strategic initiatives.

Stakeholder Communications

On the same day, DF Deutsche Forfait AG also published a statement in accordance with § 40 Abs. 1 WpHG, aimed at ensuring the widespread dissemination of information across Europe. This communication is part of the company’s ongoing efforts to keep stakeholders informed about significant developments and changes within the organization.

Strategic Expansion into Blood Plasma Market

In a significant strategic move, DF Deutsche Forfait AG has entered the blood plasma market through its newly established subsidiary, Deutsche Blutplasma HP GmbH. This subsidiary, under the umbrella of DF Health & Pharma Holding GmbH, signed a purchase agreement on April 30, 2025, marking the company’s foray into the healthcare sector. This expansion aligns with DF Deutsche Forfait AG’s broader strategy to diversify its service offerings and explore new growth opportunities beyond traditional financial services.

Conclusion

DF Deutsche Forfait AG’s successful financial year and strategic expansion into the blood plasma market underscore its resilience and adaptability in a competitive industry landscape. As the company continues to innovate and expand, stakeholders can anticipate further developments and growth in the coming years. For more information, stakeholders are encouraged to visit the company’s website at www.dfag.de .